HIND
Vyome Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.22
−0.45%Aug 28, 2026, 20:43 UTC
Vyome Holdings appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026, succeeding Robert Dickey, who resigned as Interim Chief Financial Officer effective August 31, 2026.
Aug 25, 2026, 00:00 UTC
Vyome Holdings reported Q2 2026 revenue of $58,546, a net loss of $720,000, and a diluted loss per share of $0.10, with cash and cash equivalents of $7.9 million as of the period end.
Jul 1, 2026, 12:00 UTC
Vyome Holdings, Inc. received a granted patent from the China National Intellectual Property Administration covering its besifloxacin topical gel program.
Source: